-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Preclinical Indicators and Dementia
Digital Technology for Early Detection of Neurodegenerative Disease (BBC News / EDoN)
Summary The Early Detection of Neurodegenerative Diseases (EDoN) initiative, with backing from Alzheimer’s Research UK, is working to develop wearable devices which will collect data to help detect the early stages of Alzheimer’s Disease and other neurodegenerative diseases. Full Text … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Quick Insights, UK, Universal Interest
|
Tagged Accelerating Detection of Disease Programme, Alan Turing Institute, Alzheimer's Disease: Diagnosis, Alzheimer’s Disease, Alzheimer’s Research UK (ARUK), Artificial Intelligence (AI), ARUK: Alzheimer’s Research UK, Asymptomatic Alzheimer’s Disease, Automatic Speech Analysis, BBC Health News, BBC Technology News, Behavioural Biomarkers, Benefits of Early Detection, Big Data, Bill and Melinda Gates Foundation, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, CrawfordWorks, David Cameron, David Cameron: Former Prime Minister, Digital Biomarkers, Digital Diagnostic Tools, Digital Fingerprints, Digital Technology, Digital Technology and Innovation, Early Detection of Alzheimer’s Disease, Early Detection of Disease, Early Detection of Neurodegenerative Diseases, Early Detection of Neurodegenerative Diseases (EDoN), Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnosis of Dementia, Early Recognition of Alzheimer’s Disease Using Digital Technology, Early Recognition of Neurodegenerative Diseases Using Digital Technology, EDoN Clinical Support Group, EDoN Cohorts and Biomarkers Working Group, EDoN Digital Platform Working Group, EDoN Digital Support Group, EDoN Digital Toolkit, EDoN Digital Tools Working Group, EDoN Fingerprint Analytics Working Group, EDoN White Paper, Ethical Considerations, Ethical Sharing of Data Between Organisations, Fingerprint Analytics, Gait: an Integrative Measure of Health, Heart Rate, Iceland Foods Charitable Foundation, Information Technology, International and Independent External Advisory Board, Investment in Information Technology, Machine Learning Models, Medopad, Mild Cognitive Impairment (MCI), Mindstrong Health, MRC Harwell Institute, National Hospital for Neurology and Neurosurgery: University College London, National Physical Laboratory, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Newcastle University, Non-Invasive Biomarkers, Optimising Benefits of Digital Technology, Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Dementia and Associated Lifestyle Changes, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Preclinical Phase of Dementia, Prodromal Alzheimer's Disease, Prodromal Dementia, Rates of Conversion From Mild Cognitive Impairment to Dementia, Research Informatics, Sleep Patterns, Smart Phone apps, Smart Sensors, Smart Watches, Target Discovery and Preclinical Validation, Tencent, The Rt Hon David Cameron: Chair of EDoN Board, The Rt Hon David Cameron: President of Alzheimer’s Research UK, Timely / Preclinical Neurodegenerative Diseases Diagnosis, Timely Screening / Preclinical Neurodegenerative Disease, University College London, University of Cambridge, University of Exeter, University of Oxford Big Data Institute, Walking Speed: a Behavioural Biomarker for Neurocognitive and Physical Decline, Wearable Devices, Wearable Monitoring Equipment, Wearable Sensors, Wearable Technology, Wearables (Technology)
|
Leave a comment
Summary of Recent Progress in Alzheimer’s Disease Prevention Trials (CTAD / JPAD)
Summary The following article summarises a round-up of present understanding and developments reflected in current and planned prevention trials, as discussed at a EU / US / Clinical Trials in Alzheimer’s Disease (CTAD) Task Force meeting, as of December 2016-7. … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Quick Insights
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Disease Co-operative Study - Activities of Daily Living Scale (ADCS-ADL), Alzheimer’s Disease Prevention Trials, Alzheimer’s Prevention Initiative (API), Alzheimer’s Prevention Initiative Study, Alzheimer’s Therapeutic Research Institute (ATRI), Amsterdam IADL Questionnaire, Amyloid and Tau Imaging, Amyloid and Tau PET, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study, Banner Alzheimer's Institute (Arizona), Biological Markers, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brigham and Women's Hospital, Canada, CHU Toulouse (France), Cognitive Function Instrument, Cognitive Outcome Measures, Cogstate iPad C3 Battery, Collaboration for Alzheimer’s Prevention (CAP), Composite Measures (sic Cognitive Composites), Conversion to Dementia From Prodromal Disease, Dementia Prevention, Dementia Research and Drug Development, Dementia Risk Prevention, Dementia Risk Reduction and Prevention, Denali Therapeutics (South San Francisco), Department of Epidemiology and Public Health: CHU Toulouse, DIAN-TU Study, DIAN-TU Trial, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU), Drug Development for Alzheimer's Disease, Drug-Development Pipeline, EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force, EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force (December 2016 Meeting), European Medicines Agency, Everyday Cognition (E-Cog) Scale, F-31073 (Toulouse), F. Hoffmann-LaRoche Ltd (Basel), France, Free and Cued Selective Reminding Test (FCSRT), Functional Activities Questionnaire (FAQ), Gerontopole Toulouse: Toulouse University Hospital, Global R&D Partners LLC (San Diego), Harvard Medical School, Imaging, Inc. (New York), Informant-Reported Outcome Measures, Innovation Infrastructure, Johns Hopkins University School of Medicine Baltimore, Journal of Prevention of Alzheimer’s Disease (JPAD), Keck School of Medicine: University of Southern California, Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study, McGill University, Molecular Imaging; Mild Behavioral Impairment, Multi-Domain Alzheimer’s Prevention Trial (MAPT), National Institutes of Health’s Accelerating Medicines Partnership (AMP), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurology (FDA), Next Generation (NexGen) Prevention Trial, NIH Toolbox Cognition Battery (NIHTB-CB), Non-Invasive Biomarkers, Outcome Measures, Participation in Research, Patient Reported Outcome Measures, Pentara Corporation (Salt Lake City), PET, Pfizer, Plasma Biomarkers, Preclinical Alzheimer's Disease, Preclinical Alzheimer’s Cognitive Composite (PACC), Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prevention, Prevention Agenda, Prevention Agenda Linking Dementia and Other Non-Communicable Diseases, Prevention Approaches, Prodromal Alzheimer's Disease, Promisary Science, Recruitment and Retention, Regulation and Drug Development For Early-Stage Alzheimer's Disease, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Research Promotion, Sharing Knowledge and Information, Slowing Progression of Disease (Stabilisation), Switzerland, Tau PET, Technology and Infrastructure Development, TOMMORROW Study, UMR1027 Inserm, United States, University College London, University Hospital of Montpellier, University of Southern California, University of Toulouse III, USA, Washington University School of Medicine
|
Leave a comment
New Drugs for Dementia (POST Note PN 535)
Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program
|
Leave a comment
Further Press Releases and Documents Relating to the 2016 Alzheimer’s Association International Conference (Alzheimer’s Association International Conference)
Summary A list of press-releases is available relating to some of the main presentations at the Alzheimer’s Association International Conference, held in Toronto last week. Full Text Link Reference Alzheimer’s Association International Conference® 2016. List of Press Releases. [Toronto. Online]: … Continue reading →
Posted in Antipsychotics, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Statistics, Universal Interest
|
Tagged 2016 Alzheimer’s Association International Conference (AAIC®2016), ADAPT-FS Research Group, Alzheimer Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's and Dementia: The Journal of the Alzheimer's Association, Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study (ADAPT-FS), Alzheimer's Disease Neuroimaging Initiative, Alzheimer’s Association, Alzheimer’s Association AAIC Press Office, Alzheimer’s Association International Conference® (AAIC®) 2016, Alzheimer’s Disease and Related Dementias (ADRD) Milestones (United States), Alzheimer’s Disease Research in Ibero America, Amyotrophic Lateral Sclerosis (ALS), Australian Reduction in Use of Antipsychotics in Dementia Care, Avoidable Hospital Admissions, Avoidable Hospitalizations of People With Alzheimer’s Disease: Cost to Medicare (USA), Behavioural and Psychological Symptoms of Dementia (BPSD), Beta-Amyloid PET Imaging, Canadian Research: Advances in Dementia Care, Celecoxib, Celecoxib (Selective COX-2 Inhibitor), Centro de Investigatición y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Dementia Risk Prevention, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia-Related Misdiagnosis, Dementia-Related Misdiagnosis (Male), Disclosure, Disclosure of Risk Marker Status, Disclosure Protocols for Disclosing APOE Genotype for Risk of Dementia, Epidemiology of Alzheimer's disease in Ibero America, Estudio Nacional de Salud y Envejecimiento en México (ENASEM), Ethical Challenges in Preclinical Alzheimer’s Disease Studies and Trials, Ethical Considerations, Ethical Dilemmas, Ethics, Ethics and Consent, Eye Tests for Detection of Memory Decline and Dementia, Flanders-Belgian Patient Group, Formal Education and Complex Work (Cognitive Reserve), French Three-City Study, Frontotemporal Lobar Degeneration (FTLD), Genome-Wide Association Studies, Genome-Wide Association Studies (GWAS), Genome-Wide Association Study, Genotyping, Ibero America, International Genomics of Alzheimer's Project (IGAP), Latin America, Low Testosterone and Risk of Dementia, Men Receiving Dementia-Related Misdiagnoses More Than Women, Mild Behavioral Impairment (MBI), Milestones for Care and Support in U.S. National Plan to Address Alzheimer's Disease, Naproxen, Naproxen (Nonselective Cyclooxygenase [COX] Inhibitor), Neurodegeneration, Neurodegenerative Disease Research, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, p.R47H rs75932628 in TREM2 (Encoding the Triggering Receptor Expressed on Myeloid Cells 2 Gene on Chromosome 6p21), Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Reduction of Systematic Sedation in Dementia Care, Research and Development, Research and Innovation, Research Commitment, Risk Prevention, Risk Reduction, Risk Reduction (Formerly Termed Prevention by WDC), SABE (Salud Bienestar y Envejecimiento), Single SNP Associations in Flanders-Belgian AD Cohort, Smell and Eye Tests for Detection of Memory Decline and Dementia, Smell Tests For Detection of Memory Decline and Dementia, SNP rs75932628, Stopping Systemic Sedation, Systemic Sedation, Tau Pathogenesis, Tau Therapeutic Strategies, Testosterone Depletion and Increased Risk of Dementia, Three-City Study, Treating People with Alzheimer’s Disease Increases Survival and Reduces Cost of Care (vs. Non-Treatment), TREM2 R47H as a Risk Factor, USA National Plan to Address Alzheimer's Disease, Vascular Care Intervention To Prevent Dementia
|
Leave a comment
European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)
Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer’s Disease Biomarkers, Behavioural and Psychiatric Symptoms of Dementia, Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, Cardiovascular Adverse Events, Clinical Diagnostic Criteria, Committee for Medicinal Products for Human Use (CHMP), Comparison IWG and NIA-AA Criteria for Clinical Diagnosis of Alzheimer´s Disease, Diagnostic Tests, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnostic Criteria, EMA Central Nervous System Working Party, EMA: European Medicines Agency, Enrichment of Study Populations, European Medicines Agency, European Medicines Agency (EMA), Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Guideline on Clinical Investigation of Medicines for Alzheimer’s Disease and Other Dementias, Guideline on Medicinal Products for the Treatment of Alzheimer’s Disease and Nine Other Dementias, International Organisations, International Programmes, International Working Group (IWG), Long-Term Efficacy and Safety Studies, Medical Research, Medicines Development, Medicines Mechanism of Action, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurological Adverse Events, Neurological Disorders, Novel Targets in Neurodegeneration, Ordering of Alzheimer's Disease Biomarkers, Pharmaceutical Industry, Pharmacological Research, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Psychiatric Adverse Events, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Safety and Efficacy Markers, Stratification of Subgroups (Clinical Trials), Target Discovery and Preclinical Validation, Therapeutic Target(s): Identification, Timely Diagnosis
|
Leave a comment
Spatial Navigation Tests For Disorientation May Identify Preclinical Alzheimer’s Disease? (BBC News / Science / JGCR / Brain)
Summary A German study indicates that persons with a high genetic risk of developing Alzheimer’s Disease might be identified early by monitoring their performance in tests involving navigation through a virtual maze. Full Text Link Reference Virtual reality maze ‘predicts … Continue reading →
Posted in BBC News, Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest
|
Tagged APOE e4 Carriers, APOE-4 Allele, Apoe-ε4 Allele, APOE-ε4 Carriers, Apolipoprotein E (APOE) e4 Allele, Apolipoprotein E (Apoe)-ε4 Genotype, At-Genetic-Risk Alzheimer's Disease, BBC Health News, Behavioural Biomarkers, Big Data, Bonn, Brain (Journal), Center for Economics and Neuroscience: University of Bonn, Computer Games, Conversion to Dementia From Prodromal Disease, Dementia, Dementia Research, Department of Clinical Educational and Health Psychology: University College London, Department of Clinical Neurosciences: University of Cambridge, Department of Electrical Engineering: University College London, Department of Epileptology: University of Bonn, Department of Neuropsychology: Ruhr-University Bochum, Department of Psychiatry: University of Cambridge, Department of Psychology: Ulm University, Department of Psychology: University of Bonn, Diagnosis, Differential Diagnosis, Digital Diagnostic Tools, Disorientation, Donders Institute for Brain Cognition and Behaviour: Radboud University, Early Detection of Preclinical Disease, Early-Onset Alzheimer's Gene, Early-Onset Dementia, Entorhinal Cortex, Entorhinal Dysfunction in Adults at Genetic Risk for Alzheimer’s Disease, Gamification, German Center for Neurodegenerative Diseases (DZNE), German Centre for Neurodegenerative Diseases (Bonn), Germany, Germany. Department of Epileptology: University of Bonn, Grid-Cell-Like Representations, Grid-Cell-Like Representations in Adults at Genetic Risk for Alzheimer’s Disease, HTC Vive iVR Equipment, Information Technology, Institute of Cognitive Neuroscience: Ruhr-University Bochum, Institute of Cognitive Neuroscience: University College London, Journal of Geriatric Care and Research (JGCR), MRC Cognition and Brain Sciences Unit: University of Cambridge, Netherlands, Neurodegenerative Disease, Non-Invasive Biomarkers, Pre-Dementia (MCI), Preclinical Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Radboud University, Risk Factors, Ruhr-University Bochum, Science (American Association for the Advancement of Science), Science Journal, Sea Hero Quest (SHQ) Game, Spatial Disorientation, Spatial Navigation Benchmarks, Spatial Navigation Tests of Disorientation, Ulm University, University College London, University of Bonn, University of Cambridge, Virtual Mazes
|
Leave a comment